G
GenFlow
OrganizationHeard in 1 episode across 1 show since Sep 2026
A biotechnology company developing gene-therapy and longevity programs, including work involving SIRT6 and age-related diseases.
Episodes
1
across 1 show
First heard
Sep 2026
Expert statements
2
1 positive
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 0 |
What experts have said about GenFlow
2 statements · 1 positive · 1 neutral
GenFlow intends to license human programs after Phase 2 efficacy signals.
“our model is to license at Phase 2.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 44:41
GenFlow expects business-development proceeds to advance three human programs.
“Getting these trade sales or business development deal will definitely allow us to move our programs, our 3 programs in humans: glaucoma, MASH, and sarcopenia.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 45:05
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring GenFlow, newest first
